SENSS has substantial experience in reviewing and modelling neonatal diabetes screening. We have conducted multiple projects that have led to publications in high-impact journals.
Neonatal diabetes is a rare form of high blood sugar that appears in very young babies, usually before they are six months old. Unlike the more common types of diabetes people usually hear about, this version is caused by a tiny "glitch" in a single gene that affects how the baby's body produces or uses insulin. Screening for this condition involves checking a baby’s blood sugar levels and, if they are high, performing a genetic test to find the exact cause. Because it is so rare, it can sometimes be mistaken for other illnesses, so screening is the only way to get the right diagnosis.
We need this screening because catching it early is life-changing for the baby and their family. If it isn't found quickly, the baby can become dangerously ill, which can lead to problems with their growth and brain development. The most important reason for screening is that once doctors identify the specific genetic cause, many of these babies can stop taking daily insulin shots and switch to a simple pill instead. This treatment is often much more effective, easier for parents to manage, and gives the baby the best possible start in life.
Cost-effectiveness model (2022-2023)